Abstract
Objectives: The patient’s subjective well-being and attitude toward antipsychotic medication are considered to be important for compliance. Methods: Self-rating Well-being Neuroleptic Scale (SWN) was applied to evaluate the patients´ subjective well-being.We also administered the Drug Attitude Inventory (DAI) to evaluate the attitude of the study subjects toward antipsychotic medication.
Results: Seventy-five outpatients (women N = 25) at the average age of 34.6 years (median 32 years) with the diagnosis of schizophrenia were included into the study. The patients with the most pronounced subjective well-being were in remission, treated with monotherapy, and low doses of antipsychotic drugs.
Conclusion: Subjective well-being is increasingly being accepted as a valid and important measure of antipsychotic treatment outcomes and tolerability.